Head-to-head · WeighScore
BloomWell Rx vs Hims & Hers
By GLP-1 ScorecardUpdated
Score comparison
Hims & Hers has the higher recorded score — 75.6/100 to 61.3/100.
Hims & Hers grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Mass-market app-first program with nationwide reach and consumer-grade polish.
We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.
Factor by factor
These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.
The numbers
Swipe or scroll to compare both providers.
| Metric | BloomWell Rx | Hims & Hers |
|---|---|---|
| WeighScore | 61.3/100 | 75.6/100 |
| Grade | C | C |
| Site position | #335 | #56 |
| Semaglutide | $199/mo (starting dose, compounded) | $199/mo |
| Tirzepatide | $249/mo (starting dose, compounded) | Not disclosed |
| Coverage | Coverage not published | All 50 states |
| Brand-name access | Not confirmed | Not confirmed |
| Oral / sublingual | Not confirmed | Not confirmed |
Site position #335 · C
Strengths
- Transparent pricing — compounded semaglutide from $199/mo, tirzepatide (GLP-1/GIP) from $249/mo
- Free initial visit; fully online process with flexible dosing options
- Discloses meds are compounded by a licensed third-party pharmacy; also offers NAD+, sermorelin, glutathione
- Full legal suite published (Terms, Privacy, HIPAA Notice, Returns & Refunds)
What to consider
- 'Starts at' pricing — final cost depends on dose and plan
- Compounding pharmacy partner not named ('licensed third-party pharmacy')
- LegitScript certification was not documented on the public pages reviewed
- Operating medical entity not clearly named (site operated by a marketing agency)
Site position #56 · C
FDAWarning letter issued to Hims & Hers Health, Inc. dba Hims in September 2025. See the FDA warning-letter database.
Strengths
- Nationwide
- Polished app
- Strong brand trust
What to consider
- Tirzepatide pricing inconsistently disclosed
- Industry-wide compounding scrutiny
Featured provider
CoreAge Rx
CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.
Commercial relationships affect this placement. The score comparison above is separate.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.